TEVA (tevapharm.com) Forward P/E Multiple

Symbol and logo of brand Teva Pharmaceuticals (TEVA)

Rising biosimilar sales and reduced generic costs are creating positive momentum for Teva Pharmaceutical Industries (TEVA). Effective global distribution minimizes drug shortages, supporting the operating margin. Large-scale decentralized production reduces transportation costs for pharmacy deliveries. The company's expected price-to-earnings ratio helps assess the market discount, with the indicator currently standing at 13.60.

Projected Price to Earnings Ratio: Teva Pharma (TEVA) for 07/04/2022 - 11/18/2026

Teva (TEVA) - metric breakdowns and financial figures

Basic company analysis:TEVA tevapharm.com
Brand item of tevapharm.com

Forward P/E is calculated as the ratio of the current market price to the consensus earnings per share forecast. This metric identifies asset overheating by correlating quotes with expected business performance. For Teva Pharmaceutical Industries (TEVA), with its strict FDA oversight and patent barriers, this indicator confirms earnings stability. The current value of 13.60 reflects the market valuation of the company's potential. By analyzing the forward P/E of the company, an investor determines the risk of purchasing an undervalued or overvalued asset.